162 related articles for article (PubMed ID: 33288595)
1. Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
Cojocaru E; Thway K; Fisher C; Messiou C; Zaidi S; Miah AB; Benson C; Gennatas S; Huang P; Jones RL
Anticancer Res; 2020 Dec; 40(12):7003-7007. PubMed ID: 33288595
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Merimsky O; Meller I; Flusser G; Kollender Y; Issakov J; Weil-Ben-Arush M; Fenig E; Neuman G; Sapir D; Ariad S; Inbar M
Cancer Chemother Pharmacol; 2000; 45(2):177-81. PubMed ID: 10663634
[TBL] [Abstract][Full Text] [Related]
3. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.
Hartmann JT; Oechsle K; Huober J; Jakob A; Azemar M; Horger M; Kanz L; Bokemeyer C
Invest New Drugs; 2006 May; 24(3):249-53. PubMed ID: 16133789
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
Ferraresi V; Ciccarese M; Cercato MC; Nuzzo C; Zeuli M; Di Filippo F; Giannarelli D; Cognetti F
Cancer Chemother Pharmacol; 2008 Dec; 63(1):149-55. PubMed ID: 18351342
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network.
Smrke A; Frezza AM; Giani C; Somaiah N; Brahmi M; Czarnecka AM; Rutkowski P; Van der Graaf W; Baldi GG; Connolly E; Duffaud F; Huang PH; Gelderblom H; Bhadri V; Grimison P; Mahar A; Stacchiotti S; Jones RL
ESMO Open; 2022 Jun; 7(3):100522. PubMed ID: 35717681
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience.
Schmitt T; Kosely F; Wuchter P; Schmier JW; Ho AD; Egerer G
Onkologie; 2013; 36(7-8):415-20. PubMed ID: 23921760
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
Von Burton G; Rankin C; Zalupski MM; Mills GM; Borden EC; Karen A
Am J Clin Oncol; 2006 Feb; 29(1):59-61. PubMed ID: 16462504
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.
Martin-Liberal J; López-Pousa A; Martínez-Trufero J; Martín-Broto J; Cubedo R; Lavernia J; Redondo A; López-Martín JA; Mulet-Margalef N; Sanjuan X; Tirado ÒM; Garcia-Del-Muro X
Target Oncol; 2018 Feb; 13(1):81-87. PubMed ID: 29177953
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.
Luo Z; Zhang X; Peng W; Wu X; Wang H; Yu H; Wang J; Chang J; Hong X
Medicine (Baltimore); 2015 Oct; 94(43):e1777. PubMed ID: 26512574
[TBL] [Abstract][Full Text] [Related]
14. Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report.
Silvestris N; Piscitelli D; Crucitta E; Fiore M; De Lena M; Lorusso V
J Chemother; 2003 Oct; 15(5):507-9. PubMed ID: 14603882
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
Tanaka K; Joyama S; Chuman H; Hiraga H; Morioka H; Yoshikawa H; Hosaka M; Takahashi M; Kubo T; Hatano H; Kaya M; Toguchida J; Nishida Y; Nagano A; Tsumura H; Iwamoto Y
World J Surg Oncol; 2016 Dec; 14(1):306. PubMed ID: 27931230
[TBL] [Abstract][Full Text] [Related]
16. [Gemcitabine in advanced stage soft tissue sarcoma: a phase II study].
Amodio A; Carpano S; Manfredi C; Del Monte G; Di Lauro L; Gionfra T; Conti F; Paoletti G; Lopez M
Clin Ter; 1999; 150(1):17-20. PubMed ID: 10367540
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
18. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
Boven E; Schipper H; Erkelens CA; Hatty SA; Pinedo HM
Br J Cancer; 1993 Jul; 68(1):52-6. PubMed ID: 8318420
[TBL] [Abstract][Full Text] [Related]
19. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma.
Pender A; Davis EJ; Chauhan D; Messiou C; Al-Muderis O; Thway K; Fisher C; Zaidi S; Miah A; Judson I; van der Graaf W; Keedy VL; Benson C; Jones RL
Med Oncol; 2018 Aug; 35(10):131. PubMed ID: 30128716
[TBL] [Abstract][Full Text] [Related]
20. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
Altwegg R; Ychou M; Guillaumon V; Thezenas S; Senesse P; Flori N; Mazard T; Caillo L; Faure S; Samalin E; Assenat E
World J Gastroenterol; 2012 Mar; 18(12):1357-64. PubMed ID: 22493549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
